Biofourmis will use the funding to scale its commercial operations to provide post-acute patient monitoring services and is preparing for the commercial launch of its software as a service (SaaS) health analytics platform, biovitals.
Biovitals uses artificial intelligence (AI) to integrate and analyse continuous physiology data from clinical-grade wearables and to detect personalised patterns that can predict a patient’s health deterioration. This continuous monitoring platform alerts medical professionals to intervene days before a critical event.
Kuldeep Singh Rajput, Founder & CEO of Biofourmis quoted US findings that one in five patients return to hospital within 30 days of being discharged. “The two words you would rather not hear at a hospital, are 'welcome back', especially if you have just been discharged," he said.
“At Biofourmis, we are reinventing remote patient monitoring that will increase patient outcomes and reduce readmissions following discharge. Our proprietary AI technology identifies health deterioration weeks in advance of readmission to hospital. Ultimately, our goal is to be an integrated solution and platform that actually reaches the patients, physicians/care teams, payers, and hospital providers.”
Anvesh Ramineni, Director at NSI Ventures, a Singapore-headquartered venture capital firm called Biofourmis an innovative healthtech company. “Biofourmis is a testament to the quality of talent and innovation emerging from the region," he said.
Kuldeep Singh Rajput, Founder & CEO of Biofourmis quoted US findings that one in five patients return to hospital within 30 days of being discharged. “The two words you would rather not hear at a hospital, are 'welcome back', especially if you have just been discharged," he said.
“At Biofourmis, we are reinventing remote patient monitoring that will increase patient outcomes and reduce readmissions following discharge. Our proprietary AI technology identifies health deterioration weeks in advance of readmission to hospital. Ultimately, our goal is to be an integrated solution and platform that actually reaches the patients, physicians/care teams, payers, and hospital providers.”
Anvesh Ramineni, Director at NSI Ventures, a Singapore-headquartered venture capital firm called Biofourmis an innovative healthtech company. “Biofourmis is a testament to the quality of talent and innovation emerging from the region," he said.
Fernand Lendoye, MD, Aviva Ventures in Asia added, “Biofourmis is a great example of Aviva Ventures’ ideal of a new technology business that’s tackling a huge problem for customers and society with global implications, and has the ability to scale up."
Explore:
Read the TechTrade Asia blog post mentioning Biofourmis at CommunicAsia2017
Explore:
Read the TechTrade Asia blog post mentioning Biofourmis at CommunicAsia2017
No comments:
Post a Comment